Brazilian Journal of Veterinary Medicine, 2022 Feline leukemia virus (FeLV) infection was discovered over 50 years ago; however, the serious clinical changes associated with FeLV infection still have great importance in the diagnosis, prevention, and clinical management of symptomatic patients ...
Carla Regina Gomes Rodrigues Santos +5 more
doaj +4 more sources
Adverse events of raltegravir and dolutegravir [PDF]
Aids, 2017 To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Prospective cohort study.
Hansjakob Furrer, Huldrych F Gunthard
exaly +7 more sources
Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. [PDF]
PLoS ONE, 2014 HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) for HIV infection, has been implicated in HAART-associated cardiovascular complications.
Xiaoxuan Zhang +11 more
doaj +6 more sources
Features of application of raltegravir in HIV-infected patients with different somatic pathologies
Журнал инфектологии, 2021 Purpose of the study. Evaluation of the efficacy, safety and tolerability of raltegravir regimens in HIV-infected patients with concomitant pathology in real clinical practice.Materials and methods.
N. V. Sizova +2 more
doaj +3 more sources
Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique
Iraqi Journal of Pharmaceutical Sciences, 2018 The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone s630 was utilized.
Ahmed S. Abdul Jabbar
doaj +2 more sources
Journal of Virus Eradication, 2015 Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich +16 more
doaj +2 more sources
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. [PDF]
PLoS ONE, 2014 The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed.
Jonathan Z Li +30 more
doaj +6 more sources
Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada [PDF]
BMJ OpenIntroduction Raltegravir is a potent HIV-integrase strand transfer inhibitor (INSTI). Despite its strong activity against HIV-1 strains resistant to other antiretroviral drug classes, it is usually used in combination with other antiretroviral drugs due ...
Salmaan Kanji +6 more
doaj +2 more sources
Long-term efficacy and safety of raltegravir in the management of HIV infection
Infection and Drug Resistance, 2014 Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Raltegravir is ...
Liedtke MD +4 more
doaj +1 more source
Acta Crystallographica Section E Structure Reports Online, 2013 The hydrated title compound [systematic name:N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-{1-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-ylcarbonyl)amino]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide monohydrate], C20H21FN6O5·H2O, is recognised as the first HIV integrase inhibitor.
Yamuna, T. S. +4 more
openaire +4 more sources